Olaparib is the first cancer drug to target inherited genetic mutations . 
 Up to 30 per cent of men with advanced prostate cancer have tumours with genetic defects  - and they responded well to olaparib . 
 Drug prolongs time a sufferer can live without disease getting worse . 
 